Fiona G.M. Taylor and Ian R. Swift, Mayday University Hospital, Croydon; Gina Brown, The Royal Marsden National Health Service (NHS) Foundation Trust, Sutton, Surrey; Philip Quirke, Leeds Institute of Molecular Medicine, University of Leeds; David Sebag-Montefiore, St James's Institute of Oncology Bexley Wing, St James University Hospital, Leeds; Richard J. Heald and Brendan J. Moran, Pelican Cancer Foundation, North Hampshire Hospital, Basingstoke, Hampshire; Paris Tekkis, The Royal Marsden NHS Foundation Trust, London, United Kingdom; and Lennart Blomqvist, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden.
J Clin Oncol. 2014 Jan 1;32(1):34-43. doi: 10.1200/JCO.2012.45.3258. Epub 2013 Nov 25.
The prognostic relevance of preoperative high-resolution magnetic resonance imaging (MRI) assessment of circumferential resection margin (CRM) involvement is unknown. This follow-up study of 374 patients with rectal cancer reports the relationship between preoperative MRI assessment of CRM staging, American Joint Committee on Cancer (AJCC) TNM stage, and clinical variables with overall survival (OS), disease-free survival (DFS), and time to local recurrence (LR).
Patients underwent protocol high-resolution pelvic MRI. Tumor distance to the mesorectal fascia of ≤ 1 mm was recorded as an MRI-involved CRM. A Cox proportional hazards model was used in multivariate analysis to determine the relationship of MRI assessment of CRM to survivorship after adjusting for preoperative covariates.
Surviving patients were followed for a median of 62 months. The 5-year OS was 62.2% in patients with MRI-clear CRM compared with 42.2% in patients with MRI-involved CRM with a hazard ratio (HR) of 1.97 (95% CI, 1.27 to 3.04; P < .01). The 5-year DFS was 67.2% (95% CI, 61.4% to 73%) for MRI-clear CRM compared with 47.3% (95% CI, 33.7% to 60.9%) for MRI-involved CRM with an HR of 1.65 (95% CI, 1.01 to 2.69; P < .05). Local recurrence HR for MRI-involved CRM was 3.50 (95% CI, 1.53 to 8.00; P < .05). MRI-involved CRM was the only preoperative staging parameter that remained significant for OS, DFS, and LR on multivariate analysis.
High-resolution MRI preoperative assessment of CRM status is superior to AJCC TNM-based criteria for assessing risk of LR, DFS, and OS. Furthermore, MRI CRM involvement is significantly associated with distant metastatic disease; therefore, colorectal cancer teams could intensify treatment and follow-up accordingly to improve survival outcomes.
术前高分辨率磁共振成像(MRI)评估环周切缘(CRM)受累的预后相关性尚不清楚。本项对 374 例直肠癌患者的随访研究报告了术前 MRI 评估 CRM 分期、美国癌症联合委员会(AJCC)TNM 分期与临床变量与总生存(OS)、无病生存(DFS)和局部复发时间(LR)之间的关系。
患者接受了协议规定的高分辨率盆腔 MRI 检查。记录肿瘤距直肠筋膜的距离≤1mm 为 MRI 累及 CRM。多变量分析中使用 Cox 比例风险模型,在校正术前协变量后,确定 MRI 评估 CRM 与生存结果的关系。
存活患者的中位随访时间为 62 个月。MRI 清晰 CRM 患者的 5 年 OS 为 62.2%,而 MRI 累及 CRM 患者为 42.2%,风险比(HR)为 1.97(95%CI,1.27 至 3.04;P<0.01)。MRI 清晰 CRM 患者的 5 年 DFS 为 67.2%(95%CI,61.4%至 73%),而 MRI 累及 CRM 患者为 47.3%(95%CI,33.7%至 60.9%),HR 为 1.65(95%CI,1.01 至 2.69;P<0.05)。MRI 累及 CRM 的局部复发 HR 为 3.50(95%CI,1.53 至 8.00;P<0.05)。多变量分析时,MRI 累及 CRM 是唯一与 OS、DFS 和 LR 相关的术前分期参数。
术前高分辨率 MRI 评估 CRM 状态优于 AJCC TNM 标准,可评估 LR、DFS 和 OS 的风险。此外,MRI CRM 受累与远处转移疾病显著相关;因此,结直肠癌团队可以相应地加强治疗和随访,以改善生存结果。